+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Oral Drug Delivery - Global Strategic Business Report

  • PDF Icon

    Report

  • 498 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6105950
The global market for Oral Drug Delivery was estimated at US$125.8 Billion in 2024 and is projected to reach US$180.1 Billion by 2030, growing at a CAGR of 6.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Oral Drug Delivery market.

Global Oral Drug Delivery Market - Key Trends & Drivers Summarized

Why Is Oral Drug Delivery the Preferred Route for Systemic Therapy?

Oral drug delivery remains the most widely used route for administering pharmaceuticals due to its convenience, non-invasiveness, and cost-effectiveness. It supports self-administration, improves patient compliance, and allows for consistent systemic exposure across a wide range of drug classes. Tablets, capsules, liquids, and powders are standard formats, with controlled-release and site-specific systems enhancing therapeutic outcomes.

This route is commonly used in managing chronic conditions such as diabetes, hypertension, cardiovascular disorders, neurological diseases, and infectious illnesses. For many APIs, oral delivery provides sufficient bioavailability, predictable absorption profiles, and easy formulation scalability. As a result, it continues to be the preferred choice for both over-the-counter medications and long-term prescription therapies.

What Technological Innovations Are Enhancing Oral Delivery Performance?

Technological advancements in drug formulation are overcoming traditional barriers such as poor solubility, low permeability, and first-pass metabolism. Techniques like solid dispersion, self-emulsifying systems, nanoencapsulation, and polymer-based carriers are improving bioavailability of poorly soluble drugs. Enteric coatings and mucoadhesive platforms are ensuring targeted delivery and protection against gastric degradation.

Modified-release systems, including extended-release tablets and osmotic pump formulations, are enabling sustained drug levels over longer durations. Multiparticulate and orally disintegrating tablets are enhancing dosing flexibility, especially in pediatric and geriatric populations. New excipient technologies and 3D printing are also facilitating personalized dose customization, supporting the rise of precision medicine in oral formulations.

Where Is Demand Expanding and Which Therapeutic Segments Lead Usage?

Demand for oral drug delivery is increasing in both developed and emerging markets, particularly in chronic disease management and home-based care. Cardiovascular, metabolic, and psychiatric drugs remain key drivers of oral formulation demand. Oncology is also adopting oral drugs for targeted therapy, especially where continuous dosing is required. Anti-infectives, gastrointestinal medications, and hormone therapies also rely heavily on oral formats.

Pediatric and geriatric populations are spurring demand for novel oral delivery options such as mini-tablets, flavored suspensions, and chewable formats. In oncology, oral targeted therapies and hormonal agents are supporting outpatient care, reducing the need for infusion visits. In low-resource settings, oral formats support large-scale public health distribution due to their ease of storage and administration.

Growth in the Oral Drug Delivery market is driven by several factors

Growth in the oral drug delivery market is driven by factors such as the rising prevalence of chronic diseases, improvements in formulation science, and increased preference for non-invasive, self-administered therapies. Advancements in solubility enhancement and controlled-release technologies are enabling better therapeutic efficacy and patient adherence.

Adoption of oral targeted drugs in oncology and long-term infectious disease treatment is expanding, supported by investments in drug stability, bioavailability, and gastrointestinal targeting. Expanding pharmaceutical production in Asia-Pacific and increasing regulatory approvals for oral formulations across diverse indications are further supporting global market growth. Demand for patient-friendly, compliance-oriented drug delivery formats is reinforcing the sustained role of oral systems in modern pharmacotherapy.

Scope Of Study:

The report analyzes the Oral Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Form (Tablets Form, Capsules Form, Drops Form, Liquid or Syrup Form); Type (Controlled Release, Orodispersible Tablets, Other Types); Therapy Area (Oncology Therapy Area, Musculoskeletal Therapy Area, Immunology Therapy Area, Gastrointestinal Therapy Area, Respiratory Therapy Area, Cardiovascular Therapy Area, Other Therapy Areas); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Diagnostic Centers End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Tablets Form segment, which is expected to reach US$72.6 Billion by 2030 with a CAGR of a 4.9%. The Capsules Form segment is also set to grow at 7.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $34.3 Billion in 2024, and China, forecasted to grow at an impressive 9.5% CAGR to reach $36.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Oral Drug Delivery Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Oral Drug Delivery Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Oral Drug Delivery Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Adare Pharma Solutions, Aquestive Therapeutics, Catalent Pharma Solutions, Croda International Plc, Entera Bio Ltd. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 48 companies featured in this Oral Drug Delivery market report include:

  • Adare Pharma Solutions
  • Aquestive Therapeutics
  • Catalent Pharma Solutions
  • Croda International Plc
  • Entera Bio Ltd.
  • Enteris BioPharma Inc.
  • Graviti Pharmaceuticals
  • LTS Lohmann Therapie-Systeme AG
  • Lyndra Therapeutics
  • Murli Krishna Pharma Pvt. Ltd.
  • Nektar Therapeutics
  • Oramed Pharmaceuticals
  • Par Pharmaceutical
  • Pfizer Inc.
  • Polymedix Technologies (Adhex)
  • Rani Therapeutics
  • Rubicon Research
  • Sigmoid Pharma
  • SPI Pharma
  • Tapemark

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Adare Pharma Solutions
  • Aquestive Therapeutics
  • Catalent Pharma Solutions
  • Croda International Plc
  • Entera Bio Ltd.
  • Enteris BioPharma Inc.
  • Graviti Pharmaceuticals
  • LTS Lohmann Therapie-Systeme AG
  • Lyndra Therapeutics
  • Murli Krishna Pharma Pvt. Ltd.
  • Nektar Therapeutics
  • Oramed Pharmaceuticals
  • Par Pharmaceutical
  • Pfizer Inc.
  • Polymedix Technologies (Adhex)
  • Rani Therapeutics
  • Rubicon Research
  • Sigmoid Pharma
  • SPI Pharma
  • Tapemark

Table Information